phase 2 retatrutide Original Article: Triple–Hormone-Receptor Agonist for Obesity — A Trial https://t.co/jNL1GNnHPT #ADA23 A Study of Retatrutide (LY3437943)

52 Among patients undergoing bio-enteric IGB placement, the prevalence of hypertension, diabetes, hypercholesterolemia, and osteoarthropathy decreased from 29%, 15%, 32%, and 25% (pre-IGB), respectively, to 16%, 10%, 21%, and 13% at 3 years post-IGB removal

Crossref 45

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: a replication study using reports to the World Health Organization pharmacovigilance database (VigiBase )

translation to human physiology is not established [2]

Plaintiffs claim the company failed to adequately warn users about the risks associated with Ozempic, Wegovy, and similar GLP-1 drugs